| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 10051559 | The Journal of Urology | 2005 | 6 Pages |
Abstract
Our results suggest that a 3-fold decreased dose of intravesical BCG is as effective as the standard dose against progression in patients with high risk stages T1G3 and Tis superficial bladder carcinoma but with significantly less toxicity.
Related Topics
Health Sciences
Medicine and Dentistry
Nephrology
Authors
JOSÃ A. MARTÍNEZ-PIÃEIRO, LUIS MARTÍNEZ-PIÃEIRO, EDUARDO SOLSONA, RAFAEL HERNÁNDEZ RODRÍGUEZ, JESÃS MARÍA FERNÁNDEZ GÃMEZ, MARCELINO GONZÁLEZ MARTÍN, JESÃS RODRÍGUEZ MOLINA, ANABEL GIMENO COLLADO, NICOLÁS FLORES, SANTIAGO ISORNA,